TAOK1
Basic information
Region (hg38): 17:29390363-29551903
Links
Phenotypes
GenCC
Source:
- intellectual disability, autosomal dominant 40 (Definitive), mode of inheritance: AD
- autosomal dominant non-syndromic intellectual disability (Supportive), mode of inheritance: AD
- complex neurodevelopmental disorder (Moderate), mode of inheritance: AD
- developmental delay with or without intellectual impairment or behavioral abnormalities (Strong), mode of inheritance: AD
- syndromic intellectual disability (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Developmental delay with or without intellectual impairment or behavioral abnormalities | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Neurologic | 31230721; 33565190 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (6 variants)
- Developmental delay with or without intellectual impairment or behavioral abnormalities (2 variants)
- Global developmental delay with or without impaired intellectual development (1 variants)
- TAOK1-related disorder (1 variants)
- Neurodevelopmental disorder (1 variants)
- Neurodevelopmental delay (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TAOK1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 15 | |||||
missense | 68 | 83 | ||||
nonsense | 17 | |||||
start loss | 0 | |||||
frameshift | 10 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
splice region | 1 | 1 | 7 | 4 | 13 | |
non coding | 2 | |||||
Total | 13 | 24 | 74 | 13 | 9 |
Highest pathogenic variant AF is 0.00000657
Variants in TAOK1
This is a list of pathogenic ClinVar variants found in the TAOK1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-29451563-CAG-C | Developmental delay with or without intellectual impairment or behavioral abnormalities | Pathogenic (Oct 26, 2022) | ||
17-29451577-T-G | Uncertain significance (Jun 04, 2024) | |||
17-29451578-G-A | TAOK1-related disorder | Benign (Sep 01, 2023) | ||
17-29451605-C-T | Likely benign (Dec 01, 2023) | |||
17-29451680-TGTAA-T | Developmental delay with or without intellectual impairment or behavioral abnormalities | Likely pathogenic (Mar 03, 2021) | ||
17-29451681-G-GT | Developmental delay with or without intellectual impairment or behavioral abnormalities | Uncertain significance (Aug 15, 2024) | ||
17-29467148-C-T | Developmental delay with or without intellectual impairment or behavioral abnormalities | Pathogenic/Likely pathogenic (Aug 23, 2022) | ||
17-29467155-T-C | Inborn genetic diseases | Uncertain significance (Jan 23, 2023) | ||
17-29467157-C-T | Inborn genetic diseases | Uncertain significance (Nov 30, 2022) | ||
17-29467165-T-G | Uncertain significance (Mar 01, 2022) | |||
17-29467174-G-A | Likely benign (Aug 01, 2023) | |||
17-29467175-G-A | Uncertain significance (Mar 01, 2022) | |||
17-29467178-A-T | Uncertain significance (Mar 01, 2022) | |||
17-29467181-A-C | Uncertain significance (Jun 29, 2021) | |||
17-29467183-G-C | Uncertain significance (Jun 26, 2024) | |||
17-29467217-G-A | TAOK1-related disorder | Pathogenic (-) | ||
17-29475668-A-G | Developmental delay with or without intellectual impairment or behavioral abnormalities | Likely pathogenic (Feb 19, 2024) | ||
17-29475675-G-A | Neurodevelopmental disorder | Uncertain significance (Dec 01, 2021) | ||
17-29475688-A-G | Developmental delay with or without intellectual impairment or behavioral abnormalities | Uncertain significance (Jan 03, 2022) | ||
17-29475692-A-C | Neurodevelopmental disorder | Likely pathogenic (May 06, 2021) | ||
17-29475698-A-G | Uncertain significance (Oct 17, 2022) | |||
17-29475712-A-G | Uncertain significance (Jun 02, 2022) | |||
17-29475754-C-T | Neurodevelopmental disorder | Uncertain significance (Aug 28, 2019) | ||
17-29475765-A-G | TAOK1-related disorder | Benign (Mar 06, 2024) | ||
17-29477661-C-T | Uncertain significance (Feb 28, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TAOK1 | protein_coding | protein_coding | ENST00000261716 | 19 | 161441 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.998 | 0.00213 | 125739 | 0 | 9 | 125748 | 0.0000358 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.82 | 234 | 553 | 0.423 | 0.0000300 | 6629 |
Missense in Polyphen | 23 | 132.82 | 0.17317 | 1671 | ||
Synonymous | 0.920 | 162 | 178 | 0.912 | 0.00000843 | 1801 |
Loss of Function | 6.31 | 11 | 66.5 | 0.165 | 0.00000431 | 678 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000290 | 0.0000290 |
Ashkenazi Jewish | 0.0000993 | 0.0000992 |
East Asian | 0.0000553 | 0.0000544 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000265 | 0.0000264 |
Middle Eastern | 0.0000553 | 0.0000544 |
South Asian | 0.000133 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade. {ECO:0000269|PubMed:12665513, ECO:0000269|PubMed:13679851, ECO:0000269|PubMed:16407310, ECO:0000269|PubMed:17396146, ECO:0000269|PubMed:17900936}.;
- Pathway
- MAPK signaling pathway - Homo sapiens (human);EGF-Core;Regulation of Microtubule Cytoskeleton;MAPK Signaling Pathway;Signal Transduction;Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal;Amplification of signal from the kinetochores;Mitotic Spindle Checkpoint;Cell Cycle Checkpoints;RHO GTPases Activate Formins;RHO GTPase Effectors;Signaling by Rho GTPases;Mitotic Prometaphase;Separation of Sister Chromatids;Mitotic Anaphase;Mitotic Metaphase and Anaphase;M Phase;Cell Cycle;Resolution of Sister Chromatid Cohesion;Cell Cycle, Mitotic;p38 MAPK signaling pathway
(Consensus)
Recessive Scores
- pRec
- 0.145
Intolerance Scores
- loftool
- 0.102
- rvis_EVS
- -0.62
- rvis_percentile_EVS
- 17.16
Haploinsufficiency Scores
- pHI
- 0.277
- hipred
- Y
- hipred_score
- 0.696
- ghis
- 0.623
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.975
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Taok1
- Phenotype
Gene ontology
- Biological process
- activation of MAPKK activity;activation of MAPK activity;microtubule cytoskeleton organization;DNA repair;protein phosphorylation;cellular response to DNA damage stimulus;negative regulation of microtubule depolymerization;mitotic G2 DNA damage checkpoint;activation of JUN kinase activity;signal transduction by protein phosphorylation;stress-activated protein kinase signaling cascade;activation of protein kinase activity;positive regulation of stress-activated MAPK cascade;regulation of actin cytoskeleton organization;positive regulation of JNK cascade;protein autophosphorylation;regulation of cytoskeleton organization;neuron cellular homeostasis;regulation of microtubule cytoskeleton organization;execution phase of apoptosis;positive regulation of protein acetylation
- Cellular component
- nucleus;cytoplasm;cytosol;microtubule cytoskeleton;perinuclear region of cytoplasm;extracellular exosome
- Molecular function
- protein kinase activity;protein serine/threonine kinase activity;MAP kinase kinase kinase activity;protein binding;ATP binding;kinase activity;transferase activity;alpha-tubulin binding;protein serine/threonine kinase activator activity;tau protein binding;beta-tubulin binding;tau-protein kinase activity